In terms of treatment outcomes, the LGBTQ+ community continues to face significant disparities. For instance, a recent study in JAMA on breast cancer outcomes reported that those from sexual and gender minority groups were more likely to face delays in diagnosis. LGBTQ+ patients were also more likely to decline oncologist-recommended therapies while experiencing a three-fold…
FDA accepts priority review for BMS’s relatlimab and nivolumab in melanoma
Bristol Myers Squibb (NYSE: BMY) has won priority review for its Biologics License Application for the fixed-dose combination of the checkpoint inhibitors relatlimab and nivolumab to treat patients 12 and older who weigh at least 40 kg (88 pounds) with unresectable or metastatic melanoma. Relatlimab would be a novel lymphocyte-activation gene 3 (LAG-3) blocking antibody.…